IL307194A - Pharmaceutical compositions comprising zolmitriptan - Google Patents

Pharmaceutical compositions comprising zolmitriptan

Info

Publication number
IL307194A
IL307194A IL307194A IL30719423A IL307194A IL 307194 A IL307194 A IL 307194A IL 307194 A IL307194 A IL 307194A IL 30719423 A IL30719423 A IL 30719423A IL 307194 A IL307194 A IL 307194A
Authority
IL
Israel
Prior art keywords
pharmaceutical preparations
preparations containing
containing zolmitriptan
zolmitriptan
pharmaceutical
Prior art date
Application number
IL307194A
Other languages
English (en)
Hebrew (he)
Inventor
Michael Wood
James Lillie
Original Assignee
Maplight Therapeutics Inc
Michael Wood
James Lillie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maplight Therapeutics Inc, Michael Wood, James Lillie filed Critical Maplight Therapeutics Inc
Publication of IL307194A publication Critical patent/IL307194A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL307194A 2021-03-25 2022-03-24 Pharmaceutical compositions comprising zolmitriptan IL307194A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163165938P 2021-03-25 2021-03-25
US202263306377P 2022-02-03 2022-02-03
PCT/US2022/021738 WO2022204399A1 (en) 2021-03-25 2022-03-24 Pharmaceutical compositions comprising zolmitriptan

Publications (1)

Publication Number Publication Date
IL307194A true IL307194A (en) 2023-11-01

Family

ID=83397893

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307194A IL307194A (en) 2021-03-25 2022-03-24 Pharmaceutical compositions comprising zolmitriptan

Country Status (10)

Country Link
US (1) US20240189240A1 (enExample)
EP (1) EP4313037A4 (enExample)
JP (1) JP2024512069A (enExample)
KR (1) KR20240004330A (enExample)
AU (1) AU2022246101A1 (enExample)
BR (1) BR112023019407A2 (enExample)
CA (1) CA3213383A1 (enExample)
IL (1) IL307194A (enExample)
MX (1) MX2023011240A (enExample)
WO (1) WO2022204399A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117017983B (zh) * 2023-10-09 2023-12-22 中山大学 曲普坦类药物在制备抗感染药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20041689A1 (it) * 2004-09-01 2004-12-02 Bojidar Mihaylov Stankov Nuove formulazioni di rilascio controllato contenenti 5-idrossitriptofano e triptofano
EP2240022B1 (en) * 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
US20100179202A1 (en) * 2009-01-14 2010-07-15 Ajanta Pharma Limited. Orally disintegrating composition of zolmitriptan
MY169068A (en) * 2012-04-18 2019-02-12 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
MX2016010213A (es) * 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
DK3261640T3 (da) * 2015-02-25 2022-07-11 Univ California 5ht-agonister til behandling af epilepsilidelser
JP2021529158A (ja) * 2018-06-19 2021-10-28 ナショナル ユニバーシティー オブ シンガポールNational University of Singapore 様々な適応症についての生物学的利用能を向上させるための5−ヒドロキシトリプトファンの製剤
CA3158781A1 (en) * 2019-10-23 2021-04-29 Michael Wood Methods of treating the symptoms of autism spectrum disorder

Also Published As

Publication number Publication date
US20240189240A1 (en) 2024-06-13
AU2022246101A1 (en) 2023-10-12
EP4313037A1 (en) 2024-02-07
JP2024512069A (ja) 2024-03-18
CA3213383A1 (en) 2022-09-29
WO2022204399A1 (en) 2022-09-29
MX2023011240A (es) 2024-01-12
KR20240004330A (ko) 2024-01-11
EP4313037A4 (en) 2025-02-26
BR112023019407A2 (pt) 2023-11-28

Similar Documents

Publication Publication Date Title
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
EP4045480A4 (en) PHARMACEUTICAL FORMULATIONS
HRP20220837T8 (hr) Terapeutski pripravci koji sadrže deuterirane ili djelomično deuterirane n,n-dimetiltriptaminske spojeve
MA56049A (fr) Formulations stabilisées contenant des anticorps anti-angptl3
IL284733A (en) Pharmaceutical delivery compositions and uses thereof
KR102735988B9 (ko) 치료 항체 제제
IL285674A (en) Pharmaceutical formulations
IL282032A (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
MA55362A (fr) Formulations stabilisées contenant des anticorps anti-il-33
EP3960152A4 (en) COSMETIC PREPARATIONS
IL287443A (en) Dosage regimens for and compositions including anti-rsv antibodies
EP3746080A4 (en) PHARMACEUTICAL FORMULATIONS
EP4015001A4 (en) Oral pharmaceutical composition
JP1738571S (ja) 薬用パッケージ
IL282591A (en) Aminopeptidase a inhibitors and pharmaceutical compositions comprising the same
IL279877A (en) Ivosidenib forms and pharmaceutical compositions
CR20220587A (es) Formulaciones farmacéuticas
DK4027973T3 (da) Formuleringer til lægemiddeladministration
EP4434969A4 (en) ANTI-SARS-CoV-2 MEDICATION
HUE061877T2 (hu) Ciklosporin-analógok gyógyszerkészítményei
PL3787596T3 (pl) Ulepszone formulacje farmaceutyczne
IL307928A (en) Pharmaceutical compositions comprising picroside
EP3965739C0 (en) DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE TABLETS
EP4083213A4 (en) Cancer gene therapy drug
IL312073A (en) Pharmaceutical compositions of efruxifermin